press release – Parents Of Allergic Children http://parentsofallergicchildren.org/ Wed, 13 Apr 2022 11:46:40 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://parentsofallergicchildren.org/wp-content/uploads/2021/06/icon-5.png press release – Parents Of Allergic Children http://parentsofallergicchildren.org/ 32 32 Altamira Therapeutics completes patient enrollment in house dust mite allergy trial with Bentrio https://parentsofallergicchildren.org/altamira-therapeutics-completes-patient-enrollment-in-house-dust-mite-allergy-trial-with-bentrio/ Tue, 15 Mar 2022 13:05:11 +0000 https://parentsofallergicchildren.org/altamira-therapeutics-completes-patient-enrollment-in-house-dust-mite-allergy-trial-with-bentrio/ Enter Wall Street with StreetInsider Premium. Claim your one week free trial here. HAMILTON, BERMUDA/ACCESSWIRE/March 15, 2022/ Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing treatments that address significant unmet medical needs, today announced the completion of patient enrollment in its Bentrio” trial for house dust mite allergic rhinitis. Domestic (“HDM”) will release […]]]>

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


HAMILTON, BERMUDA/ACCESSWIRE/March 15, 2022/ Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing treatments that address significant unmet medical needs, today announced the completion of patient enrollment in its Bentrio” trial for house dust mite allergic rhinitis. Domestic (“HDM”) will release initial trial results in the second quarter of 2022.

The trial, which enrolled a total of 37 patients with a history of perennial allergic rhinitis (“PAR”) caused by exposure to HDM, is designed to assess the effectiveness of Bentrio” in the treatment of PAR in a room environmental exposure (EEC), i.e. under controlled HDM exposure. Study participants were randomized in a three-period open-label crossover design to receive either Bentrio” as a single dose or double, i.e. no treatment before exposure to HDM for three hours. The primary endpoint will be the change in Total Nasal Symptom Score (TNSS) from baseline. The trial is being conducted at a single study site in Canada.

“House dust mite allergies are a very common problem, especially in more humid geographies, and can cause severe suffering and reduced quality of life,” commented Thomas Meyer, Founder, Chairman and CEO of Altamira. Therapeutics. “Following the positive results of our previous clinical investigation of Bentrio in grass pollen allergic rhinitis, we expect this new study to add to the growing body of evidence demonstrating the protective effects of Bentrio against multiple airborne allergens. in the air. In the meantime, we are continuing the commercial roll-out of Bentrio, helping to provide relief to the many allergy sufferers who were looking for an effective treatment without any drugs or preservative ingredients.”

About dust mite allergies

HDM allergens are the leading cause of respiratory allergies (i.e. allergic rhinitis and allergic asthma), with prevalence estimates of allergen sensitization ranging between 65 and 130 million people in the population worldwide, i.e. up to 50% in asthmatic patients.1 In the US population aged 6 and older, house dust mite allergens are the second most common source of sensitization just after plant-based allergens (20.3 and 27.1%, respectively).2 Unlike plant-based allergens, which tend to be seasonal (eg pollen/hay fever), HDMs can be present all year round. Symptoms of HDM allergies include sneezing, runny or stuffy nose, itching, coughing, difficulty breathing, chest tightness, or pain.

The references

1Calderon et al. (2015), Respiratory allergy caused by dust mites: what do we really know?, J Allergy Clin Immunol 136(1):38-48.

2Saleo et al. (2014), Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Survey (NHANES) 2005-2006. J Allergy Clin Immunol 134(2):350-9.

About Bentrio”

Bentrio” (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. When applied to the nose, Bentrio” forms a protective gel layer on the nose. nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with the cells; in addition, the composition serves to bind these particles and to promote their evacuation and to moisten the nasal mucosa. Together, this is designed to reduce the risk of viral upper respiratory infections and promote relief of allergy symptoms.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutic products that address significant unmet medical needs. The Company is currently active in three fields: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore” / SemaPhore” platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio”; commercial) or for the treatment of vertigo (AM-125; Phase 2) and the development of therapies for the intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3) The company was founded in 2003 and is based in Hamilton, Bermuda, with its principal operations in Basel, Switzerland The shares of Altamira Therapeutics Ltd.

Forward-looking statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of fact statements and may include statements that address future operational, financial or business performance or Altamira Therapeutics’ strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimates”, “predicts”, “plans”, “potential”, “outlook” or “continues”, or the negative form of these terms or any other comparable terminology. Forward-looking statements are based on the current expectations and beliefs of management and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such statements.These risks and uncertainties include, but are not limited to, approval and timing of commercialization of AM-301, Altamira Therapeutics’ need and ability to secure substantial additional funding to further develop its product candidates, timing and conduct of studies clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position and the financial condition of Altamira Therapeutics’ ‘Altamira Therapeutics, including the impact of any future acquisitions, dispositions, partnerships, licensing transactions or changes to Altamira Therapeutics’ capital structure, including future issuances of securities. These risks and uncertainties also include, but are not limited to, those described under “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the fiscal year ended December 31, 2020, and in other documents filed by Altamira Therapeutics with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to such risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics undertakes no obligation to update them in light of new information, future developments or otherwise, except as required by applicable law. required.

Investor contacts:
Stephen Kilmer
646.274.3580
[email protected]

THE SOURCE: Altamira Therapeutic

See the source version on accesswire.com:
https://www.accesswire.com/693111/Altamira-Therapeutics-Completes-Patient-Enrollment-in-House-Dust-Mite-Allergy-Trial-with-Bentrio

]]>
Atopic Dermatitis Treatment Market New Opportunities, Key Trends, Rising Demand, Emerging Growth, Business Development https://parentsofallergicchildren.org/atopic-dermatitis-treatment-market-new-opportunities-key-trends-rising-demand-emerging-growth-business-development/ Tue, 15 Mar 2022 04:33:00 +0000 https://parentsofallergicchildren.org/atopic-dermatitis-treatment-market-new-opportunities-key-trends-rising-demand-emerging-growth-business-development/ The Atopic Dermatitis Treatment Market provides in-depth analysis of current trends and future estimates. PORTLAND, OREGON, USA, March 15, 2022 /EINPresswire.com/ — Atopic dermatitis is a chronic disease that causes inflammation of the skin and results in red, itchy, swollen and cracked skin. The affected area may cause a discharge of white fluid and will […]]]>

The Atopic Dermatitis Treatment Market provides in-depth analysis of current trends and future estimates.

PORTLAND, OREGON, USA, March 15, 2022 /EINPresswire.com/ — Atopic dermatitis is a chronic disease that causes inflammation of the skin and results in red, itchy, swollen and cracked skin. The affected area may cause a discharge of white fluid and will require treatment. Atopic dermis usually begins in childhood and can worsen with age. The cause of atopic dermatitis involves a genetic disorder, environmental exposure, immune system dysfunction, and difficulty in skin permeability.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
• Sanofi SA
• Allergan Plc.
• Novartis International SA
• Bristol-Myers Squibb
• Bayer AG
• Meda Pharmaceuticals
• Anacor Pharmaceutical Inc.
• Pfizer
• Astellas Pharma Inc.
• Regeneron Pharmaceuticals

https://www.alliedmarketresearch.com/request-sample/3353

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

• The study provides an in-depth analysis of the global Atopic Dermatitis Treatment market, with current trends and future estimates to elucidate investment pockets.
• A comprehensive analysis of the factors driving and restraining the market growth has been provided.
• The report offers quantitative analysis to help stakeholders capitalize on market opportunities.
• A thorough analysis of the different segments determines the different products available in the market.
• Major players have been profiled and their strategies thoroughly analyzed to predict the competitive market outlook.

https://www.alliedmarketresearch.com/purchase-enquiry/3353

The atopic dermatitis treatment market is driven by factors such as new product launches and a large pool of patients. However, factors such as stringent government regulations for product approval are expected to restrain the market growth. The development and progress of health in emerging countries should offer new opportunities during the period of analysis.

The atopic dermatitis treatment market is segmented on the basis of drug class, mode of administration, distribution channel and geography. Based on drug class, the market is segmented into corticosteroids, calcineurin inhibitors, immunosuppressants, biological therapy, PDE-4 inhibitor, antibiotics, antihistamines and emollients. By mode of administration, the market is bifurcated into topical, oral, and injectable. By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, pharmacies, mail-order pharmacies, and dermatology clinics. By geography, it was analyzed across North America, Europe, Asia-Pacific and LAMEA.

https://www.alliedmarketresearch.com/atopic-dermatitis-treatment-market

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬

Digital health market

electrophysiology market

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐌𝐚𝐫𝐤𝐞𝐭:

AMR introduces its premium subscription-based online library Avenue, designed specifically to provide a unique and cost-effective solution for businesses, investors and universities. With Avenue, subscribers can benefit from a comprehensive repository of reports on over 2,000 niche industries and over 12,000 company profiles. Additionally, users can get online access to quantitative and qualitative data in PDF and Excel formats, as well as analyst support, customization, and updated versions of reports.

𝐆𝐞𝐭𝐆𝐞𝐭 𝐭𝐨 𝐭𝐢𝐦𝐞 𝐭𝐡𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐚𝐧𝐝 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 all 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐚𝐧𝐝 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 all all 𝐭𝐢𝐦𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐚𝐧𝐝 𝐭𝐢𝐦𝐞

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 :

Allied Market Research (AMR) is a full-service market research and business consulting division of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market areas. AMR offers its services in 11 industry sectors, including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverage, Energy & Power, semiconductors and electronics, automotive and transport, ICT and media, aerospace and defense and BFSI.

We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. Allied Market Research CEO Pawan Kumar helps inspire and encourage everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. All data presented in the reports we publish are drawn from primary interviews with senior executives from leading companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.

David Correa
Allied Analytics LLP
800-792-5285
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn

]]>
These are the 10 “Allergy Capitals” of America in 2022 https://parentsofallergicchildren.org/these-are-the-10-allergy-capitals-of-america-in-2022/ Fri, 11 Mar 2022 22:17:00 +0000 https://parentsofallergicchildren.org/these-are-the-10-allergy-capitals-of-america-in-2022/ According to the Asthma and Allergy Foundation of America, more than 50 million Americans have some type of allergy, and many of them are seasonal pollen allergies. The AAFA has released its 2022 list of the so-called “Allergy Capitals” of the United States, a tradition for the foundation since 2003. According to AAFA, the list […]]]>

According to the Asthma and Allergy Foundation of America, more than 50 million Americans have some type of allergy, and many of them are seasonal pollen allergies.

The AAFA has released its 2022 list of the so-called “Allergy Capitals” of the United States, a tradition for the foundation since 2003.

According to AAFA, the list ranks the 100 hardest cities to live in for seasonal allergy sufferers based on spring and fall pollen data, allergy medication use and the number of allergy sufferers. certified allergists or immunologists in each location.

Kenneth Mendez, CEO and President of AAFA, said more than 24 million people in the United States suffer from seasonal allergic rhinitis – a condition that produces a runny nose, congestion, sneezing and itching. He said seasonal allergies can also trigger an asthma attack.

“We are seeing spikes in ER visits that coincide with spikes in pollen seasons,” Mendez said in a press release issued by AAFA. “About 3,600 people a year die from asthma, so it’s important to treat and manage asthma and allergy triggers where you live.”

To manage seasonal allergies, the AAFA has several recommendations, such as keeping windows closed during pollen seasons, using HEPA filters on air conditioning systems, taking showers before bed, and wearing a mask and hair covering. outside. Get even more tips here.

There are several over-the-counter medications that can help manage seasonal allergies. Speak to your doctor to determine which is best for you.

10 “Allergy Capitals” of the United States

10. Albany, NY

9. New Haven, Connecticut

8. Buffalo, New York

7. Hartford, Connecticut

6. Oklahoma City, Oklahoma

5. San Antonio, TX

4. Richmond, Virginia

3. McAllen, TX

2. Wichita, Kansas

1. Scranton, Pennsylvania

]]>
FinCap supports the government’s commitment to lead safely https://parentsofallergicchildren.org/fincap-supports-the-governments-commitment-to-lead-safely/ Thu, 10 Mar 2022 20:15:00 +0000 https://parentsofallergicchildren.org/fincap-supports-the-governments-commitment-to-lead-safely/ Friday, March 11, 2022, 9:15 a.m.Press release: FinCap FinCap welcomes the government’s continued commitment to loan security. Laws requiring all lenders to have robust processes to sell only appropriate and affordable loans will continue to prevent harm in our communities. This morning, Minister Clark announced practical updates that target lenders by further clarifying the checks […]]]>

FinCap welcomes the government’s continued commitment to loan security. Laws requiring all lenders to have robust processes to sell only appropriate and affordable loans will continue to prevent harm in our communities.

This morning, Minister Clark announced practical updates that target lenders by further clarifying the checks they must do before selling a loan.

Previous government reforms to credit agreements and the Consumer Finance Act (CCCFA) are already creating a more level playing field for whānau.

Financial mentors report that the most blatantly unfair lending practices are disappearing while troubled borrowers have more options. This means more well-being for our whānau and our communities.

In a letter to FinCap MPs and others earlier this week, we highlighted the introduction in 2021 of clear requirements for what lenders must include in an affordability assessment as a game changer.

These checks mean that all borrowers can expect lenders not to look to put them on the path to financial disaster with unaffordable interest and fees or unsuitable arrangements.

North Harbor Budgeting Service financial mentor David Verry said CCCFA reform has so far meant mobile or payday lenders – like truck shops – have all but disappeared from the landscape.

“The number of people we had before – I had clients who had five or six payday loans – I don’t see payday loans now, or anything like a payday loan,” he said.

Debtfix director and co-founder Christine Liggins says the reform means fewer people are being sold a loan they cannot afford.

“A real and honest affordability assessment will easily stop a spiral of debt because it takes into account all the costs – all the things that people don’t think about.”

FinCap Senior Policy Advisor Jake Lilley said they will continue to support changes that protect all whānau from financial hardship.

“Too often financial mentors see lenders collect loans that were never going to work and immediately put a whānau on a difficult journey where it was hard to buy kai.

“Safe lending laws with affordability assessment financial health checks mean lenders cannot overlook the damage they could or have caused,” he says.

“As the Commerce Commission recently revealed, predatory flex-fee practices that are banned overseas are commonplace in the auto loan industry. It’s important that borrowers have safe lending laws that allow them to support.”

FinCap will continue to participate in the Council of Financial Regulators’ investigation into the implementation of CCCFA reforms to share the benefits of safe lending laws, as well as instances where some lenders are still avoiding liability for unfair conduct.

The financial capacity building sector shared their thoughts on what the CCCFA reform package means so far for the whānau they support in this video: https://www.youtube.com/watch?v=aqNDg4_O8H4 .

Remarks

  • FinCap is the umbrella organization for Aotearoa’s 900+ financial mentors
  • The package of reforms planned by the CCCFA over the past few years includes interest rate caps for high-cost loans, certifications for mobile lenders (or truck shops), and sanctions for senior executives and administrators who do not comply with the changes.

© Scoop Media

]]>
Here are the tips officials are sharing for Consumer Protection Week https://parentsofallergicchildren.org/here-are-the-tips-officials-are-sharing-for-consumer-protection-week/ Wed, 09 Mar 2022 01:42:30 +0000 https://parentsofallergicchildren.org/here-are-the-tips-officials-are-sharing-for-consumer-protection-week/ I’m not a fan of making every free calendar day a holiday, and “National Consumer Protection Week” doesn’t sound the most exciting. But it does spur massive sharing of the best tips and tools for avoiding scams and fraud, which I think makes it more useful than National Ice Cream Day. So, in honor of […]]]>

I’m not a fan of making every free calendar day a holiday, and “National Consumer Protection Week” doesn’t sound the most exciting.

But it does spur massive sharing of the best tips and tools for avoiding scams and fraud, which I think makes it more useful than National Ice Cream Day.

So, in honor of the sexiest and most convenient week of the year, here are some of the resources I’ve seen floating around that will empower you as a consumer.

Lodging

If you or someone you know is facing illegal evictions, rent increases, or housing discrimination, check out my Feb. 10 column on local resources for tenants.

I’ve since heard that some legal aid organizations are overwhelmed, so check out lawhelpca.org/topic/housing for more options. You can also contact the Sonoma County Tenants Union Hotline at 707-387-1968.

The California Department of Justice asks victims of such violations to send advice or file complaints to housing@doj.ca.gov. In a similar vein, the agency recently launched a Housing Crisis Strike Force and housing portal (oag.ca.gov/housing) that offers many resources for renters and homeowners in difficult situations.

For California homeowners struggling to finance their home, watch out for foreclosure salvage scams. Any foreclosure consultants or loan modification service companies that require money up front do so illegally, so never agree to pay fees for loans before the services are provided.

Additionally, officials warn never to make your mortgage payments to anyone other than your lender or loan officer, so be wary of any mortgage advisor who tries to get payments redirected to you through them. (You can check if a foreclosure consultant is registered with the Attorney General’s office or if a mortgage lender or managing agent is licensed at docqnet.dfpi.ca.gov/licensessearch/.)

To file a complaint against mortgage brokers, you can contact the Department of Financial Protection and Innovation at dfpi.ca.gov/file-a-complaint/ or call 866-275-2677.

Debts and loans

The state has a number of resources about debt collectors and your rights at oag.ca.gov/consumers/general/debt-collectors. (For example, there are certain rules regarding harassing calls.) If you receive a debt collection call, require written notice (a “validation notice”) to review before giving out personal or financial information to avoid scams. .

When it comes to predatory lending, experts recommend avoiding payday lenders as much as possible, as the rates on these loans are usually much higher than those on credit cards and other loans. (The average annual percentage rate for payday loans is 372%.)

You can search for a payday lender’s license and any disciplinary action taken against it at dfpi.ca.gov/local.

Other scams

This year has seen the rise of the COVID-19 testing scam, a phenomenon our region has not escaped.

As the pandemic has receded and testing has become available again, this is thankfully less of an issue now, but stick to county-approved testing locations as much as possible, lists of which you can always find at covid19.ca.gov/ get-local-information/#County-websites.

Another scam to watch out for these days are fraudulent charities. They unfortunately arise in times of urgent need and disaster, such as the war in Ukraine, when people seek to show their support. Don’t let that deter you from sending help, but slow down and do your research.

You can take steps such as checking a charity’s registration status and viewing organizations’ ratings from charity watchdog groups such as the Better Business Bureau’s Wise Giving Alliance, CharityWatch, or CharityNavigator. Double-check for copycat charities that look like well-known organizations but may, for example, have a slightly different URL.

It’s also a good idea to run fundraising campaigns on Google before donating to see what others are saying. You can report charities in bad faith at oag.ca.gov/charities/complaints.

Speaking of scammers taking advantage of times of stress, with skyrocketing energy bills, watch out for utility bill scams, too. In 2021, PG&E reportedly received more than 11,000 reports of scammers posing as the utility, with customers losing more than $600,000 through fraudulent payments.

Beware of those who may demand immediate payment or risk cutting off service or requesting financial information under the guise of offering you a refund or discount. If in doubt, hang up and call PG&E yourself.

More broadly, for phone or internet scams or any other scams, AARP has a Fraud Watch Network with resources that will help anyone spot scams and a hotline (877-908-3360) with specialists fraud that can help victims who have been targeted.

On March 10, the Network is hosting an event with the Federal Trade Commission at 11 a.m. on dealing with the fallout from a scam and tips on recovering lost money. You can register at aarp.cventevents.com/event/390dbc6e-8273-40ac-81e8-fc861c927fe7/summary.

In general, Californians who are victims of fraud or scams can report violations of consumer protection laws to the Department of Justice at oag.ca.gov/report. You can also contact your local county consumer protection office.

“If you have been exploited by a predatory lender, are facing abusive debt collection practices, have been unlawfully evicted, or have information about other violations of the law, please file a complaint with from my office,” Bonta said in a press release. Monday.

“The leads we get from the public help us identify where companies are trying to circumvent the law – and help us hold companies accountable.”

“In Your Corner” is a new column that puts monitoring reports to work for the community. If you have a concern, advice or hunch, you can contact “In Your Corner” columnist Marisa Endicott at 707-521-5470 or marisa.endicott@pressdemocrat.com. On Twitter @InYourCornerTPD and Facebook @InYourCornerTPD.

]]>
Devonian Health Group Announces Annual and Special General Meeting Voting Results and Welcomes New Board Members https://parentsofallergicchildren.org/devonian-health-group-announces-annual-and-special-general-meeting-voting-results-and-welcomes-new-board-members/ Tue, 01 Mar 2022 14:00:00 +0000 https://parentsofallergicchildren.org/devonian-health-group-announces-annual-and-special-general-meeting-voting-results-and-welcomes-new-board-members/ QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian“or the”society”) (TSX v: GSD), a clinical-stage botanical pharmaceutical company focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announces the voting results of its annual and special general meeting held on February 25, 2022 via videoconference. The number of shares represented in person or […]]]>

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian“or the”society”) (TSX v: GSD), a clinical-stage botanical pharmaceutical company focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announces the voting results of its annual and special general meeting held on February 25, 2022 via videoconference. The number of shares represented in person or by proxy represented 66.72% of the votes on all issued and outstanding shares of Devonian Health Group Inc.

Election of directors

The nine (9) nominees nominated for election to the Devonian Board of Directors and listed in the Company’s Management Information Circular, dated January 26, 2022, were elected by a majority of votes cast. by the shareholders present in person or represented by proxy at the meeting as follows:

name

Votes for (%)

Votes retained (%)

André P. Boulet

97.56

2.44

Sybil Dahan

90.08

9.92

Guy Dancosse

97.63

2.37

Louis Flemish

97.71

2.29

Terry L. Fretz

97.71

2.29

Martin Moreau

97.65

2.35

Pierre J. Montanaro

97.63

2.37

Denis Poirier

97.63

2.37

Erick Shield

97.63

2.37

Appointment of auditors

In addition, Devonian today announces that 100% of its shareholders have approved the reappointment of PricewaterhouseCoopers LLP as auditor of the Company until the next annual meeting of shareholders.

Ratification and Confirmation of the Company’s Stock Option Plan

Devonian also announces today that 99.77% of its shareholders have ratified and confirmed the company’s stock option plan.

Ratification and Confirmation of the Company’s Restricted Share Unit Plan

Devonian also announces today that 93.85% of its shareholders have ratified and confirmed the Company’s Restricted Share Unit Plan.

Ratification of Shareholder Rights Plan

Devonian today announces that 99.97% of its shareholders have ratified and affirmed the shareholder rights plan.

Issuance of subordinate voting shares

Devonian also announced today that 99.97% of its shareholders have approved the issuance of 1,311,553 subordinate voting shares at a price of $0.352 per subordinate voting share for an aggregate amount of 461,666 $.74. to 9294-5039 Québec inc., a company with which the Company does not deal at arm’s length. The subordinate voting shares are issued in satisfaction of a debt due for consulting services.

New board members

Devonian is pleased to announce the appointment of 2 new members to its Board of Directors. Joining the Board of Directors are Denis Poirier and Pierre J. Montanaro. These appointments bring the total number of members of the Company’s Board of Directors to nine.

“We are delighted to welcome these new independent directors to our Board of Directors,” said Dr. André P. Boulet PhD, Chairman of Devonian’s Board of Directors. “They bring decades of expertise and leadership in key areas such as drug commercialization and strategy implementation. I am confident they will provide valuable insights as we continue to execute our drug development strategy. botanicals.”

Denis Poirier obtained a Bachelor of Commerce from McGill University in 1978 and obtained a graduate diploma in accounting in 1980 as well as the title of chartered accountant. From 1978 to 1996, Denis worked for two different accounting firms where he mainly practiced in the fields of taxation and mergers and acquisitions. Denis joined the Royal Bank of Canada from 1996 to 1998 where, after leading the $50 million initial public offerings of Spectra Premium industries inc. he became their vice president of tax, financing and acquisitions and led two additional public offerings in 1998 and 1999 for an additional $150 million. In 2007, Denis oversaw the privatization of Spectra Premium industries inc. and became its chief financial officer and one of its major shareholders until 2016 when he sold his shares. During his 18 years at Spectra Premium Industries, Denis played a key role in the growth of the company where sales grew from $30 million to over $600 million and the workforce from 300 to over 1,600 following more than 20 acquisitions in Canada, the United States. and Europe and following organic growth resulting from the development of new products and new markets. Denis is recognized for his in-depth knowledge and expertise in negotiation, taxation, business valuation, financing, acquisitions, business development and strategic planning. Since 1998, Denis has also acquired expertise in boards of directors and advisory boards with 8 listed companies, private and non-profit organizations including the youth foundation of the DPJ since 2009 of which he is also the treasurer.

With a Bachelor of Commerce degree from Concordia University, Pierre Montanaro has more than 40 years of experience in the pharmaceutical and consumer products industries during which he held various management positions in marketing, sales and general management. Since December 2014, Pierre has been president of his own consulting company TriumPharma Inc., which works with local and foreign clients to acquire and commercialize pharmaceutical products in the Canadian market. Previously, he served as President and CEO of Pharmetics, a company specializing in the development and sale of pharmaceutical and natural health products. Previously, Mr. Montanaro held various management positions at Pharmascience (2003-2011), Pharmacia (2001-2003), Marion Merrell Dow/Hoechst Marion Roussel/Aventis (1994-2001) and Burroughs Wellcome (1988-1994). During his long career in the pharmaceutical industry, Mr. Montanaro has always been recognized as a goal-oriented leader with an entrepreneurial spirit and a strong sense of urgency. His skills and multiple accomplishments earned him an induction into the Pharmaceutical Industry Marketing Hall of Fame in 2006.

On a personal note, Mr. Montanaro served for more than a decade on the Board of Directors of the Nonprescription Drug Manufacturers Association of Canada. In addition, he also sat on the board of directors of Collège Gérald Godin for more than three years. Pierre Montanaro has been married to Danièle Lapierre for 45 years and is the father of two daughters, Sarah and Vanessa.

About the Devonian

Devonian Health Group Inc. is a late-stage botanical pharmaceutical company with novel therapeutic approaches to target unmet medical needs. Devonian’s primary strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of autoimmune inflammatory diseases, including but not limited to ulcerative colitis and atopic dermatitis. Based on more than 15 years of research, Devonian’s direction is further supported by a set of US-FDA regulatory guidelines promoting a more efficient drug development pathway for herbal prescription pharmaceuticals. compared to those of traditional prescription drugs. Devonian’s flagship product, Thykamine™, the first pharmaceutical product from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, antioxidant and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as a phase IIa clinical study in patients with mild to moderate distal ulcerative colitis and in a large phase 2 clinical trial in adult patients with mild to moderate atopic dermatitis. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach used with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada, where it has a state-of-the-art extraction facility with full “seed to pill” traceability. Acquired in 2018, Altius Healthcare Inc., its marketing subsidiary, offers additional diversification opportunities and growth potential. Devonian is listed on the TSXV Exchange (TSXV:GSD).

For more information, visit www.groupedevonian.com

Forward-looking statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets in which we operate and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions prove to be inaccurate. These risks and assumptions include, but are not limited to, Devonian’s ability to successfully develop, manufacture and commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, Devonian’s ability to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to differ materially from our current expectations in Devonian’s prospectus dated April 21.st2017 under the heading “Risk factors” related to Devonian’s business. Accordingly, we cannot guarantee that any forward-looking statement will materialize. We undertake no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, except as required by applicable securities laws and regulations. .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

]]>
DBV Technologies will participate in the next AAAAI 2022 https://parentsofallergicchildren.org/dbv-technologies-will-participate-in-the-next-aaaai-2022/ Tue, 22 Feb 2022 21:30:00 +0000 https://parentsofallergicchildren.org/dbv-technologies-will-participate-in-the-next-aaaai-2022/ Montrouge, France, February 22, 2022 DBV Technologies for Participate to come AAAAI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its upcoming participation in the annual scientific meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI), February 24 – February 28, […]]]>

Montrouge, France, February 22, 2022

DBV Technologies for Participate to come AAAAI 2022 Congress

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its upcoming participation in the annual scientific meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI), February 24 – February 28, 2022. Two scientific presentations were accepted, including a clinical poster and a non-clinical poster. DBV will also have a booth in the AAAAI exhibit hall.

Data that will be presented from the non-clinical poster will discuss the effect of specialist allergy care on health care utilization among children with peanut allergy in the United States, suggesting that allergy care was associated with reduced total health care costs and higher rates of epinephrine prescription. . In addition, the clinical poster will present pooled safety data from phase 3 studies of epicutaneous immunotherapy with investigational Viaskin Peanut 250 mcg in children aged 4 to 11 years, after treatment for up to 36 months in children with peanut allergy. These data informed DBV’s understanding of the healthcare ecosystem and the value proposition of Viaskin Peanut in children with food allergies.

“The data we are presenting at AAAAI this year highlights the safety and tolerability potential of epicutaneous immunotherapy and the Viaskin™ platform,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “I am delighted that we are engaging in in-depth discussions about the potential benefits of using the Viaskin™ platform to treat peanut allergy in children and to further our understanding of how the intervention of a allergist may have wider implications in the healthcare system.”

Viaskin™ Peanut (DBV712 250 μg) is the Company’s lead product candidate designed to potentially reduce the risk of allergic reactions in peanut-allergic children aged 4-11 years due to accidental exposure to peanuts. An experimental, non-invasive, once-daily patch, Viaskin Peanut seeks to deliver micrograms of peanut antigen to activate the immune system. Viaskin Peanut is DBV’s innovative approach to epicutaneous immunotherapy (EPIT), a method of delivering biologically active compounds to the immune system through intact skin.

DBV summaries:

Scientist Presentations

Both e-posters will be accompanied by recorded presentations from the authors and will be available upon request at https://annualmeeting.aaaai.org/ beginning Friday, February 25, 2021.

Please note that only registered attendees will be able to access the Poster Room, which is available through the AAAAI Virtual Platform. After the meeting, these presentations will be available on DBV’s website, www.dbv-technologies.com, for those unable to attend.

Effect of specialty allergy care on health care utilization among children with peanut allergy in the United States will be presented by Dr. Matthew J. Greenhawt, MD, Children’s Hospital Colorado, University of Colorado, Aurora, Denver.

  • Abstract number: 120
  • Date: February 26, 2022, 9:45-10:45 a.m.
  • Location: Convention Center, North Building, Lower Level, Hall 4

Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children 4-11 Years of Age will be presented by Dr. Rachel G. Robison, MD, Vanderbilt University Medical Center, Nashville, Tennessee

  • Abstract number: 097
  • Date: February 26, 2022, 9:45-10:45 a.m.
  • Location: Convention Center, North Building, Lower Level, Hall 4

About DBV Technologies
DBV Technologies is developing Viaskin™, an exclusive research technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is committed to safely transforming the care of patients with food allergies. DBV’s food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has its global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The ordinary shares of the Company are listed on compartment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the ADSs of the Company (each representing half of an ordinary share) are listed on the Nasdaq Global Select Market (Mnemo: DBVT) .

Forward-looking statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for children with peanut allergy and the potential benefits of EPIT. These forward-looking statements and estimates are neither promises nor guarantees and involve substantial risks and uncertainties. At this stage, the Company’s products have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein are the uncertainties generally associated with research and development, clinical trials and related regulatory reviews and approvals, including impact of the COVID-19 pandemic, and whether preclinical data or initial or interim clinical trial results will be predictive of future or final clinical trial results or future trial results. Additionally, the timing of any action by a regulatory entity cannot be guaranteed, particularly in light of the COVID-19 pandemic. A more detailed list and description of such risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des marchés financiers, the Company’s Securities and Exchange Commission documents and reports, including in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019, and the Company’s future filings and reports. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Except as required by applicable law, DBV Technologies assumes no obligation to update or revise the information contained in this press release.

Investor RContact
Anne Pollack
DBV Technologies
+1 (857) 529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 (646) 842-2393
angela.marcucci@dbv-technologies.com

]]>
Free EpiPen® campaign returns in response to overwhelming demand https://parentsofallergicchildren.org/free-epipen-campaign-returns-in-response-to-overwhelming-demand/ Mon, 07 Feb 2022 20:42:00 +0000 https://parentsofallergicchildren.org/free-epipen-campaign-returns-in-response-to-overwhelming-demand/ Tuesday, February 8, 2022, 9:42 a.m.Press release: New Zealand allergy Allergy New Zealand and Pub Charity revived success FundaPen campaign to deliver 3,355 free life-saving EpiPen® auto-injectors for patients with physician-diagnosed allergies who are at risk of anaphylaxis. the FundaPen2 the initiative follows the first campaign in 2019, which saw nearly 3,000 New Zealanders receive […]]]>

Allergy New Zealand and Pub Charity revived success FundaPen campaign to deliver 3,355 free life-saving EpiPen® auto-injectors for patients with physician-diagnosed allergies who are at risk of anaphylaxis.

the
FundaPen2 the initiative follows the first campaign in 2019, which saw nearly 3,000 New Zealanders receive a free EpiPen® (adrenaline auto-injector).

Allergy New Zealand’s chief executive, Mark Dixon, said: “The life-changing campaign has been wholeheartedly supported by healthcare professionals and members of the allergy community, who have been calling for its repetition ever since. that it ended in 2020”.

Pub Charity CEO Martin Cheer says, “Pub Charity is proud to support the FundaPen2
initiative. We know from past experience what a positive contribution this can make to the lives of people with severe allergies, especially those on low incomes.

Life-saving EpiPens® only last 12-18 months, are not currently funded by PHARMAC, and can cost between $120 and $350 each. Over the past 17 years, Allergy New Zealand has filed eight applications for EpiPen® auto-injectors to be publicly funded through PHARMAC.

the FundaPen2 The campaign was made possible by a generous donation of $350,000 from Pub Charity to Allergy New Zealand. The national charity will buy 3,355 EpiPen® auto-injectors from Queenstown Pharmacy, which come from a New Zealand supplier, Viatris Ltd.

Mark Dixon says the return of
FundaPen2 will help meet an important need for New Zealanders at risk of anaphylaxis, whose families/whānau are struggling to purchase an EpiPen®. “We have received so much support for FundaPen from prescribers and the allergy community, our Facebook page received over 100,000 visits in the first 24 hours after the first public launch,” he says.

“In Australia, people at risk of anaphylaxis are now eligible for two funded adrenaline auto-injectors each year. In this country, none are funded, and the speed at which free EpiPens® have been adopted under FundaPen
shows us that there are significant unmet needs.

Through the original
FundaPen campaign, which was made possible by a $300,000 donation from Pub Charity, Allergy New Zealand was able to reach those least able to afford the life-saving drug. A total of 2,875 EpiPens® were distributed between November 2019 and August 2020.

“We continue to actively campaign for EpiPens® to be publicly funded, as it is in Australia,” says Mark.

For over 40 years, Allergy New Zealand has been improving the quality of life of New Zealanders living with allergies, providing evidence-based information and support. Allergy New Zealand receives no government funding and will not receive any financial benefit from the Pub Charity donation.

Eligible patients will be eligible for
FundaPen2 from Wednesday, February 9, 2022 while supplies last.

FundaPen2™ THE FACTS

  • EpiPen® auto-injectors are available through the FundaPen2 initiative from Wednesday, February 9, 2022.
  • To obtain one of the free EpiPen® auto-injectors, families will need to speak with their family doctor or prescriber.
  • 1 EpiPen® per eligible patient.
  • The exclusive distributor is Queenstown Pharmacy (www.AllergyPharmacy.co.nz)
  • Each recipient should receive training and education on the use of the EpiPen® and the management of their allergy to avoid anaphylaxis, from their prescriber.
  • The aim of Allergy New Zealand and Pub Charity is to ensure that as many eligible patients as possible benefit from the
    FundaPen2 initiative.
  • Once 3,355 FREE EpiPen® auto-injectors have been dispensed from the Queenstown Pharmacy, normal prescribing protocols, dispensing and fees will apply.

© Scoop Media

]]>
Get the latest information on winter storms https://parentsofallergicchildren.org/get-the-latest-information-on-winter-storms/ Wed, 02 Feb 2022 14:17:50 +0000 https://parentsofallergicchildren.org/get-the-latest-information-on-winter-storms/ Winter storm forecasters predicted it blew up in central Illinois early Wednesday. Winter storm Landon swept through the Midwest bringing bands of heavy snow and wind making travel dangerous. The storm was expected to continue through most of Wednesday before a lull then pick up late before receding Thursday afternoon. Snowfall in Springfield, Illinois About […]]]>

Winter storm forecasters predicted it blew up in central Illinois early Wednesday.

Winter storm Landon swept through the Midwest bringing bands of heavy snow and wind making travel dangerous. The storm was expected to continue through most of Wednesday before a lull then pick up late before receding Thursday afternoon.

Snowfall in Springfield, Illinois

About 2.3 inches of snow had fallen in the Springfield area as of 6 a.m., according to the National Weather Service in Lincoln. This snowfall was measured near Abraham Lincoln Capital Airport.

NWS meteorologist Chuck Schaffer said the heaviest snowfall for the system will be Wednesday morning through noon, when about three to five inches is expected to fall. Another inch of snow was forecast for Wednesday afternoon, Schaffer said, followed by a long break until evening.

]]>
Registration is open for SMi’s 22nd Annual Pain Therapy Conference https://parentsofallergicchildren.org/registration-is-open-for-smis-22nd-annual-pain-therapy-conference/ Sat, 29 Jan 2022 18:53:00 +0000 https://parentsofallergicchildren.org/registration-is-open-for-smis-22nd-annual-pain-therapy-conference/ SMi Reports: Leading pain therapy conference to take place for 22nd consecutive year May 4-5, 2022 in London, UK LONDON, LONDON, UK, Jan. 29, 2022 /EINPresswire.com/ — SMi Group is pleased to announce the 22nd Annual Pain Therapy Conference to be held in London, UK on the 4th and May 5, 2022. to explore new […]]]>

SMi Reports: Leading pain therapy conference to take place for 22nd consecutive year May 4-5, 2022 in London, UK

LONDON, LONDON, UK, Jan. 29, 2022 /EINPresswire.com/ — SMi Group is pleased to announce the 22nd Annual Pain Therapy Conference to be held in London, UK on the 4th and May 5, 2022. to explore new compounds and treatments for pain: opioids and alternatives

The brochure can be downloaded from www.pain-therapeutics.co.uk/PR1

The Pain Therapeutics conference will cover key advances in pain treatment, explore late development clinical trials, new treatments for chronic conditions, technology collaboration treatments, the use of virtual reality and medical devices that perform non-invasive nerve stimulation. Industry leaders will learn about the latest advancements in the field, highlighting the use of opioids and the future of cannabinoids in pain therapy. Additionally, policy experts will provide essential regulatory perspective for this year’s program, offering exciting and comprehensive insight into the pain treatment market.

The conference also discusses how the pain industry has been affected by COVID-19, with many people suffering from pain unable to get help or treatment. Consequently, there has been pressure to ensure that newer, more effective treatments will be made available to patients. There is also a need to move away from opioid-based pain treatment.

Interested parties can register at http://www.pain-therapeutics.co.uk/pr1 – there is an early bird offer expiring on Monday 31 January where participants can save £400 on registration.

Key Conference Highlights:
• Learn about new treatments available for people with painful conditions, such as migraine, atopic dermatitis and muscle spasms
• Expand your knowledge of analgesics for the treatment of pain
• Discuss new alternative pain treatments and the use of opioids in the field
• Network with industry professionals and discuss recent advances in the industry, including updates on the latest research on personalized pain relievers
• Explore chronic pain with the perspectives of industry professionals and how transcriptomic technology is used to better understand chronic pain

SMi Group is proud to announce that the conference chair is industry expert Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc.

Keynote speakers who will be presenting include:
• Michael Seminerio, Senior Director, US Chief Medical Officer, Teva Pharmaceuticals
• Mark Field, CEO and Co-Founder, Eptiva Therapeutics Ltd.
• Joshua Cohen, Chief Medical Officer, Braeburn
• Andrea Small-Howard, President and Scientific Director, GB Sciences
• Jennifer Beierlein, Ph.D, Health Program Specialist, National Institutes of Health
• Barbara I. Karp, National Institute of Neurological Disorders and Stroke, National Institutes of Health
• Todd Krueger, President and CEO, AOBiome Therapeutics
• Arun Bhaskar, President of the British Pain Society

The full agenda and list of speakers can be found on the conference website at http://www.pain-therapeutics.co.uk/pr1

Proudly sponsored by: CDHR
For sponsorship enquiries, contact Andrew Gibbons, Sales Manager on +44 (0)20 7827 6156 or agibbons@smi-online.co.uk

For media inquiries or to request a press pass, contact Simi Sapal, Head of Marketing on +44 (0)20 7827 6162 or ssapal@smi-online.co.uk.

SMi’s 22nd Annual Pain Therapy Conference
May 4–5, 2022
London, UK
http://www.pain-therapeutics.co.uk/pr1
#SMiPain

— ENDS –

About the SMi Group:
Established since 1993, SMi Group is a global event production company specializing in B2B conferences, workshops, masterclasses and online communities. We create and organize events in the defense, security, energy, utilities, finance and pharmaceutical sectors. We pride ourselves on having access to the world’s most forward-thinking thought leaders and visionaries, enabling us to bring our communities together to learn, engage, share and network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
+442078276000
write to us here

]]>